Skip to main content
Log in

ORV 116E cost effective for prevention of rotavirus in India

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2014 Indian rupees

Reference

  • Rose J, et al. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis. PLOS One : 3 Nov 2017. Available from: URL: https://doi.org/10.1371/journal.pone.0187446

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ORV 116E cost effective for prevention of rotavirus in India. PharmacoEcon Outcomes News 791, 21 (2017). https://doi.org/10.1007/s40274-017-4505-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4505-7

Navigation